PRESS STATEMENT: Association of Reproductive Health Professionals Supports FDA Approval of Testosterone Transdermal System

Contact: Ann McCall
Phone: (202) 466-3825
E-mail: communications@arhp.org
Website: http://www.arhp.org

The Association of Reproductive Health Professionals supports FDA approval of the Testosterone Transdermal System (TTS) as a highly safe and effective treatment for hypoactive sexual desire disorder (HSDD) and respectfully recommends that the FDA move forward with the approval process for this new drug.

In the past, sexual health research has focused mostly on men’s sexual health. Female sexual health is still underrepresented and understudied. While men benefit from a number of products and attention to their sexual disorders, there are still no approved treatments for women that focus specifically on their unique sexual disorders. ARHP supports focusing on the sexual health of women, and we see the introduction of safe, effective medications for women as an excellent opportunity to discuss, in an evidence-based and appropriate manner, female sexuality. ARHP believes that HSDD is a true condition and that women who suffer from it deserve a range of treatment options. Many women with HSDD can benefit from counseling, lifestyle adaptations, or other non-medical treatments. There remain some women for whom a safe, effective medical intervention, such as TTS would be of benefit. This is particularly relevant for menopausal women, whose HSDD can have a strong biological component.